In the trials, omalizumab and multi-allergen oral immunotherapy showed alike efficacy in protecting against food allergies, ...

Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

More than a third of food-allergic kids were able to eat full servings of their trigger foods after treatment with an ...

Roche’s asthma drug Xolair appears to be safer and more effective than oral immunotherapy at treating adults and children ...

Blue Cross Blue Shield of Oklahoma (BCBS), including BCBS plans in states of Illinois, New Mexico, Texas and Montana, is ...

Omalizumab was found to be more effective than multi-allergen oral immunotherapy (OIT) in reducing allergic reactions in patients with 1 or more food allergies, according to results from Stage 2 of ...

Patients with multiple food allergies introduced allergens into their diets after using omalizumab, researchers reported at ...

Discover a study that compared the effectiveness of P043 versus omalizumab in managing uncontrolled allergic asthma.

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively ...